PNC-27 (30 mg Vial) Dosage Protocol
PNC-27 is a synthetic peptide combining the p53 MDM2-binding domain with a membrane-residence sequence, studied for selective induction of necrosis in cancer cells.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = 10 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 1 unit (0.01 mL) |
| Weeks 3–4 | 200 mcg (0.20 mg) | 2 units (0.02 mL) |
| Weeks 5–8 | 300 mcg (0.30 mg) | 3 units (0.03 mL) |
| Weeks 9–12 | 400 mcg (0.40 mg) | 4 units (0.04 mL) |
| Weeks 13–16 | 500 mcg (0.50 mg) | 5 units (0.05 mL) |
Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established. Any dosing above a few hundred micrograms per day is purely speculative.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (PNC-27, 30 mg each) | 8 weeks ≈ 1 vial (~15–20 mg total used) 12 weeks ≈ 1 vial (~25 mg total used) 16 weeks ≈ 2 vials (~35–40 mg total used) |
| Insulin Syringes (U‑100 or 30/50‑unit for precision) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle 12 weeks (1 vial): 3 mL → 1 × 10 mL bottle 16 weeks (2 vials): 6 mL → 1 × 10 mL bottle |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
PNC-27 fuses the p53 N-terminal MDM2-binding region (residues 12-26) with the leader sequence of penetratin or other membrane-residence peptides. The result selectively binds HDM-2 expressed at the cancer-cell membrane (a tumor-specific phenomenon) and triggers necrosis without affecting normal cells lacking surface HDM-2.
Potential Benefits & Side Effects
Potential Benefits
- Cancer-cell-selective necrosis in preclinical models.
- Spares normal cells lacking surface HDM-2.
- Studied in multiple solid tumor models.
Side Effect Profile
- Limited human safety data.
- Investigational compound — research only.
Lifestyle Factors
- Use is research only; not a standalone treatment.
Injection Technique
- Research protocol dictates route.